文献速递慢性静脉疾病

CEAP分类C1级伴大隐静脉反流症状患者的治疗:一项先导研究

Treatments for symptomatic class I patients in CEAP classification with saphenous vein reflux: A pilot study.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-04-06

前瞻性先导研究纳入2020年6月至2021年12月46例毛细血管扩张或网状静脉(<3mm,CEAP C1级)伴轴性大隐静脉反流及静脉淤血症状患者,按患者偏好分为弹力袜组(n=21)和腔内治疗组(n=25),比较1、3、6个月并发症、VCSS及生活质量。两组均无严重并发症,临床症状与生活质量均改善且组间无显著差异;亚组分析显示重度症状患者(治疗前VEINES-QOL/Sym评分≤90)腔内治疗改善更明显(VCSS P=0.029,VEINES-QOL/Sym P=0.030)。

要点

  • 弹力袜与腔内治疗均可改善C1级伴大隐静脉反流症状患者的临床症状和生活质量。
  • 6个月内两组VCSS、AVSS和VEINES-QOL/Sym评分无显著组间差异。
  • 重度症状患者(治疗前VEINES-QOL/Sym≤90)腔内治疗改善更明显。

核心结论

  • 弹力袜和腔内治疗均能为有症状的C1级伴反流大隐静脉患者提供临床和生活质量改善,组间无显著差异。
  • 亚组分析显示,腔内治疗在有严重症状的C1级患者中提供统计学显著改善。

研究设计与样本

  • 前瞻性先导研究,2020年6月至2021年12月纳入46例毛细血管扩张或网状静脉(<3mm,CEAP C1级)伴轴性大隐静脉反流及静脉淤血症状患者,按患者偏好分为弹力袜组(n=21)和腔内治疗组(n=25)。
  • 于治疗后1、3、6个月评估并比较两组并发症、临床改善量表(如VCSS)及生活质量(AVSS和VEINES-QOL/Sym)。

主要发现

  • 两组均无严重并发症。
  • 弹力袜组基线及治疗后1、3、6个月VCSS中位数分别为2.0(IQR 1.0-2.0)、1.0(IQR 0.5-2.0)、1.0(IQR 0.0-1.0)、0.0(IQR 0.0-1.0);腔内治疗组对应值分别为3.0(IQR 1.0-3.0)、1.0(IQR 0.0-1.0)、0.0(IQR 0.0-0.0)、0.0(IQR 0.0-0.0)。
  • 弹力袜组基线及治疗后1、3、6个月AVSS中位数分别为4.4(IQR 3.0-5.5)、2.1(IQR 1.3-4.6)、1.0(IQR 0.0-2.8)、0.0(IQR 0.0-1.8);腔内治疗组对应值分别为6.2(IQR 3.8-12.3)、1.6(IQR 0.6-2.8)、0.0(IQR 0.0-2.6)、0.0(IQR 0.0-0.4)。
  • 弹力袜组基线及治疗后1、3、6个月VEINES-QOL/Sym平均分分别为92.7±8.1、100.4±7.3、104.3±8.2、106.0±9.7;腔内治疗组对应值分别为83.6±8.0、102.9±6.6、107.9±3.9、109.6±3.7。
  • 两组VCSS、AVSS和VEINES-QOL/Sym评分均显著改善,6个月内无显著组间差异;重度症状患者(治疗前VEINES-QOL/Sym评分≤90)中腔内治疗组改善更明显(VCSS P=0.029,VEINES-QOL/Sym评分 P=0.030)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with telangiectasia or reticular veins (CEAP [clinical, etiologic, anatomic, pathophysiologic] class C1), less invasive endovenous (EV) treatments have emerged. However, no prospective studies have compared compression stockings (CSs) and EV ablation treatment for C1 symptomatic refluxing saphenous veins. The present prospective study compared the therapeutic results of the two treatment modalities. METHODS: From June 2020 to December 2021, 46 patients with telangiectasia or reticular veins (<3 mm; class C1) with axial saphenous reflux and venous congestion symptoms were prospectively enrolled. The patients were assigned to CS (n = 21) or EV treatment (n = 25), according to patient preference. Complications, clinical improvement scales (eg, the venous clinical severity score [VCSS]), and quality of life, including the Aberdeen varicose vein symptom severity score (AVSS) and venous insufficiency epidemiological and economic study - quality of life/symptoms (VEINES-QOL/Sym), were evaluated and compared between the two groups at 1, 3, and 6 months after treatment. RESULTS: No major complications occurred in either group. The median VCSS was 2.0 (interquartile range [IQR], 1.0-2.0), 1.0 (IQR, 0.5-2.0), 1.0 (IQR 0.0-1.0), and 0.0 (IQR 0.0-1.0) at baseline and 1, 3, and 6 months after treatment in the CS group, respectively. The corresponding VCSSs were 3.0 (IQR, 1.0-3.0), 1.0 (IQR, 0.0-1.0), 0.0 (IQR, 0.0-0.0), and 0.0 (IQR, 0.0-0.0) in the EV group. The median AVSS was 4.4 (IQR, 3.0-5.5), 2.1 (IQR, 1.3-4.6), 1.0 (IQR, 0.0-2.8), and 0.0 (IQR, 0.0-1.8) at baseline and 1, 3, and 6 months after treatment in the CS group, respectively. The corresponding scores were 6.2 (IQR, 3.8-12.3), 1.6 (IQR, 0.6-2.8), 0.0 (IQR, 0.0-2.6), and 0.0 (IQR, 0.0-0.4) in the EV group. The mean VEINES-QOL/Sym score was 92.7 ± 8.1, 100.4 ± 7.3, 104.3 ± 8.2, and 106.0 ± 9.7 in the CS group at baseline and 1, 3, and 6 months after treatment, respectively. The corresponding scores were 83.6 ± 8.0, 102.9 ± 6.6, 107.9 ± 3.9, and 109.6 ± 3.7 in the EV group. Both groups showed considerable improvement in the VCSS, AVSS, and VEIN-SYM/QOL scores, and no significant between-group differences were observed for ≤6 months. Among the severely symptomatic patients (pretreatment VEINES-QOL/Sym score ≤90), the EV group exhibited more marked improvement (P = .029 for the VCSS and P = .030 for the VEINES-QOL/Sym score). CONCLUSIONS: Both CSs and EV treatment provided clinical and quality of life improvement in symptomatic C1 patients with refluxing saphenous veins, with no significant between-group differences. However, a subgroup analysis revealed that EV treatment provided statistically significant improvement in the severe symptomatic C1 group.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Cho A, Ahn S, Mo H, et al. Treatments for symptomatic class I patients in CEAP classification with saphenous vein reflux: A pilot study. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37030448. doi:10.1016/j.jvsv.2023.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。